Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: AbbVie
Woman and Man
Between 18 years
and 99 years
AbbVie
Update Il y a 5 ans
Étude Intellance 1 (M13-813) : étude de phase 2-3 randomisé en double aveugle, comparant l’efficacité et la tolérance d’un traitement associant radio-chimiothérapie, temozolomide et depatuxizumab (ABT-414), par rapport à un traitement associant radio-chimiothérapie, temozolomide et placebo, chez des patients ayant un glioblastome nouvellement diagnostiqué et porteur d’un amplification d’EGFR. [Informations issues du site clinicaltrials.gov et traduites par l'INCa]
Intellance 1 (M13-813) - A randomized, placebo controlled phase 2b/3 Study of ABT-414 with concurrent chemoradiation and adjuvant temozolomide in subjects with newly diagnosed glioblastoma (GBM) with ...
Country
France
organs
Cerveau
Specialty
Radiothérapie et Chimiothérapie
,
Thérapies Ciblées
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
AbbVie Deutschland GmbH & Co. KG
Update Il y a 4 ans
A long term extension trial of BI 655066/ABBV-066 (risankizumab) in patients with moderately to severely active Crohn's disease
To investigate long-term safety of BI 655066/ABBV-066 (risankizumab), in patients with moderately to severely active Crohn`s disease, who showed a clinical response or remission on previous treatment ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
AbbVie Deutschland GmbH & Co. KG
Update Il y a 4 ans
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab in Pediatric Subjects with Moderate to Severe Ulcerative Colitis
To demonstrate the efficacy and safety, and to assess the pharmacokinetics of adalimumab administered subcutaneously (SC) in pediatric subjects with moderate to severe ulcerative colitis (UC).
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
AbbVie Deutschland GmbH & Co. KG
Update Il y a 4 ans
Randomized, Blinded, Multicenter, Phase 2 Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer Estudio en fase II, aleatorizado, enmascarado, multicéntrico y comparativo entre veliparib más FOLFIRI ± bevacizumab frente a placebo más FOLFIRI ± bevacizumab en el cáncer colorrectal metastásico previamente no tratado
The primary objectives of the study is to assess whether the addition of oral veliparib to FOLFIRI will improve progression-free survival (PFS) in subjects with metastatic colorectal cancer (mCRC). ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
AbbVie Inc
Update Il y a 4 ans
A Study Investigating the Efficacy and Safety of ABT-494 given with Methotrexate in Subjects with Rheumatoid Arthritis Who Have Had an Inadequate Response to MTX Alone. Estudio para investigar la eficacia y la seguridad de ABT-494 administrado con metotrexato en pacientes con artritis reumatoide que han presentado una respuesta insuficiente a la monoterapia con MTX
The primary objective is to compare the safety and efficacy of multiple doses of ABT-494 versus placebo in subjects with moderately to severely active RA on stable background MTX therapy who have not ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
AbbVie Deutschland GmbH & Co. KG
Update Il y a 4 ans
A Study of the Efficacy of ABT-199 (GDC-0199) in Subjects with Relapsed or Refractory or previously untreated Chronic Lymphocytic Leukemia with the 17p Deletion
Main Cohort Primary Objective: To evaluate the efficacy of venetoclax monotherapy in subjects with relapsed or refractory chronic lymphocytic leukemia (CLL) harboring the 17p deletion. Efficacy will ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
AbbVie Deutschland GmbH & Co. KG
Update Il y a 4 ans
A Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults with Chronic Hepatitis C Virus Genotype 4, 5, or 6 Infection
To assess the efficacy (SVR12) and safety of 12 weeks of treatment with the ABT-493/ABT-530 combination regimen in adults with chronic HCV genotype (GT) 4, 5, or 6 infection without cirrhosis.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
AbbVie Deutschland GmbH & Co. KG
Update Il y a 4 ans
A PHASE II, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF GDC-0199 (ABT- 199) PLUS BENDAMUSTINE PLUS RITUXIMAB (BR) IN COMPARISON WITH BR ALONE OR GDC-0199 PLUS RITUXIMAB (R) IN PATIENTS WITH RELAPSED AND REFRACTORY FOLLICULAR NON-HODGKIN’S LYMPHOMA
To evaluate the efficacy of GDC-0199 plus Bendamustine and Rituximab (BR) compared with BR alone in patients with R/R FL. To evaluate the efficacy of GDC-0199 plus rituximab in patients with Relaps...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
AbbVie Deutschland GmbH & Co. KG
Update Il y a 4 ans
A Study Evaluating Venetoclax in Combination with Azacitidine Compared with Azacitidine Alone in Subjects with Previously Untreated Higher-Risk Myelodysplastic Syndromes (MDS)
The primary objectives of the study are to: • Assess the safety profile and pharmacokinetics (PK) of venetoclax in combination with azacitidine • Determine the recommended dose (RD) and dosing sche...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
AbbVie Deutschland GmbH & Co. KG
Update Il y a 4 ans
An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes with ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
The primary objective of this study is to evaluate the effect of response to treatment (assessed by SVR12 status) on the long-term progression of liver disease in adults with chronic HCV GT1 infection...
Country
None
organs
None
Specialty
None
unknown
More information
Previous
1
2
3
4
5
6
7
8
9
10
Next